Effects of tirofiban on the reperfusion-related no-reflow in rats with acute myocardial infarction

Journal of Geriatric Cardiology

Volumn 10, Issue 1, 2013, Pages 52-58

  Liu, Xiao ^a   Tao, Gui Zhou ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Nitric oxide synthase; Tirofian; Vascular endothelial cadherin

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; TIROFIBAN; VASCULAR ENDOTHELIAL CADHERIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART RATE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NO REFLOW PHENOMENON; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION; SHAM PROCEDURE;

EID: 84879002285     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2013.01.009     Document Type: Article

References (21)

1. Chan W, Stub D, Clark DJ, et al. Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am J Cardiol 2012; 109: 478-485.
2. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 2011; 16: 244-250.
3. Heitzer T, Ollmann I, Koke K, et al. Platelet glycoprotein II b/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation 2003; 108: 536-541. (Pubitemid 36961166)
4. Liu LM, Liu YH, Zhang M, et al. Effects of tirofiban on no-reflow phenomenon and endothelial function after myocardial ischemia/reperfusion in rats. Chin J Cardiovasc Med 2008; 13: 176-180.
5. Zhao XM, Sun S, Liu XH. Experimental model of myocardial ischemia/reperfusion in rat established by ligating coronary artery with capsule. J Chin Microcirc 2007; 11: 206-208.
6. Yang YJ, Zhao JL, You SJ, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 2006; 92: 1131-1137.
7. Li XD, Yang YJ, Geng YJ, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol 2010; 299: H1255-H1261.
8. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101: 239-243. (Pubitemid 30054149)
9. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43: 276-283. (Pubitemid 38201156)
10. Yang YJ, Zhao JL, You SJ, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 2006; 92: 1131-1137.
11. Moens AL, Kietadisorn R, Lin JY, et al. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J Mol Cell Cardiol 2011; 51: 559-563.
12. Campbell R, Fisher JP, Sharman JE, et al. Contribution of nitric oxide to the blood pressure and arterial responses to exercise in humans. J Hum Hypertens 2011; 25: 262-270.
13. Gareia-Cardena G, Fan R, Stern DF, et al. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996; 271: 27237-27240. (Pubitemid 26367273)
14. Busse R, Fleming I. Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 1995; 27: 331-340.
15. Fleming I, Fisslthaler B, Dimmeler S, et al. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001; 88: E68-E75.
16. Dumitrescu C, Biondi R, Xia Y, et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci U.S.A 2007; 104: 15081-15086. (Pubitemid 47619596)
17. Qian GC, Li D, Wang HL. Vascular endothelial cadherin and function research. Foreign Medical Sciences (Section of Blood Transfusion and Heanatology) (in Chinese) 2002; 25: 354-356.
18. Dejana E, Giampietro C. Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 2012; 19: 218-223.
19. Beishuizen A, Girbes Armand RJ. Hemorrhagic shock and reperfusion injury: The critical interplay of fibrin fragments, leukocytes, and vascular endothelial- cadherin. Crit Care Med 2009; 37: 771-772.
20. Kang S, Yang YJ, Wang QZ, et al. Expressions of eNOS3 and VE-cadherin in microvascular endothelium at 7-Day of reperfused acute myocardial infarction. Cardiovascular & Haematological Disorders-Drug Targets (in Chinese) 2009; 9: 107-117.
21. Zhao KS, Huang QB. The basic mechanism of increased microvascular permeability. Chinese Journal of Pathophysiology (in Chinese) 2003; 19: 549-553.